Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients with Axial Spondyloarthritis

Arthritis Care and Research

Volumn 67, Issue 10, 2015, Pages 1475-1480

  Sieper, J ^a   Kivitz, A ^b   Van Tubergen, A ^c   Deodhar, A ^d   Coteur, G ^e   Woltering, F ^e   Landewe R ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Altoona Center for Clinical Research   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UCB PHARMA   (Belgium)

^f Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; PLACEBO; ANTIRHEUMATIC AGENT;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS QUALITY OF LIFE MEASURE; ARTICLE; BACKACHE; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; FATIGUE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES STUDY SLEEP SCALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; SLEEP DISORDER; SLEEP DISORDER ASSESSMENT; SPONDYLARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PAIN MEASUREMENT; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF REPORT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIRHEUMATIC AGENTS; CERTOLIZUMAB PEGOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT OUTCOME ASSESSMENT; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; SELF REPORT; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; TREATMENT OUTCOME;

EID: 84942163450     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22594     Document Type: Article

References (18)

1. Van der Linden S, Valkenburg HA, Cats A., Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
2. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al., The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68: 770-6.
3. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al., The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-83.
4. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al., The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
5. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
6. Ward MM., Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999; 12: 247-55.
7. Van Tubergen A, Black P, Coteur G., Are patient-reported outcome instruments for ankylosing spondylitis fit-for-purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis. Rheumatology (Oxford) E-pub ahead of print.
8. Kimel M, Revicki D, Rao S, Fryback D, Feeny D, Harnam N, et al., Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Clin Exp Rheumatol 2011; 29: 624-32.
9. Martin-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, et al., Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010; 28: 238-45.
10. Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester GR, Hiepe F, et al., Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011; 70: 996-1002.
11. Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ., Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken) 2014; 66: 1085-92.
12. Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych W, Mease P, et al., Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 2014; 73: 39-47.
13. Spritzer H., MOS sleep scale: a manual for use and scoring. Los Angeles (CA): Rand; 2003.
14. Van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al., Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68: 922-9.
15. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al., Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005; 32: 590-601.
16. Ware JE, Kosinski M, Dewey JE., How to score version 2 of the SF-36 health survey (standard and acute forms). Lincoln (RI): QualityMetric Incorporated; 2000.
17. Hultgren S, Broman JE, Gudbjornsson B, Hetta J, Lindqvist U., Sleep disturbances in outpatients with ankylosing spondylitis: a questionnaire study with gender implications. Scand J Rheumatol 2000; 29: 365-9.
18. Van der Heijde D, Maksymowych W, Landewe R, Stach C, Hoepken B, Fichtner A, et al., Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12-week magnetic resonance imaging results of RAPID-axSpA. Ann Rheum Dis 2013; 72 Suppl 3: 515-6.